Acute Myeloid Leukemia (AML)

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

By

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

By

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

By

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

By

Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

By

Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

By

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

MDS, AML a Risk With PARP Inhibitors in <i>BRCA</i> Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

By

What is the concern behind PARP inhibitors and leukemia?

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

By

Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

For adults with relapsed or refractory AML who have an IDH2 genetic mutation

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

By

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

By

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

By

The site of cancer care may partially explain survival differences between children and AYAs with ALL.

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

By

Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

By

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

By

Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-related Cancer Deaths Highest in Southern United States

By

Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

By

This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

By

Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.

Novel Therapies Needed to Improve TP53-mutant AML Outcomes

By

Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

By

Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia

By

The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.

Combination Improves Anticancer Activity of 2 Agents in Acute Myeloid Leukemia

Combination Improves Anticancer Activity of 2 Agents in Acute Myeloid Leukemia

By

Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).

Study Evaluates Gemtuzumab Ozogamicin in Older Patients With AML

Study Evaluates Gemtuzumab Ozogamicin in Older Patients With AML

By

First-line monotherapy with low-dose gemtuzumab ozogamicin significantly improved overall survival compared with best supportive care.

Blood Test Could Help Predict Acute Myeloid Leukemia Recurrence

Blood Test Could Help Predict Acute Myeloid Leukemia Recurrence

A simple blood test can identify post-chemo patients with the NPM1 gene mutation.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs